Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Regenerx Biopharmaceuticals Inc (RGRX)

Regenerx Biopharmaceuticals Inc (RGRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 26,911
  • Shares Outstanding, K 143,447
  • Annual Sales, $ 80 K
  • Annual Income, $ -1,520 K
  • 60-Month Beta 0.62
  • Price/Sales 373.75
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade RGRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/13/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1811 +3.59%
on 09/16/21
0.2505 -25.11%
on 08/17/21
-0.0674 (-26.43%)
since 08/16/21
3-Month
0.1811 +3.59%
on 09/16/21
0.3150 -40.44%
on 07/14/21
-0.1124 (-37.47%)
since 06/16/21
52-Week
0.1750 +7.20%
on 04/13/21
0.8200 -77.12%
on 02/24/21
-0.4573 (-70.91%)
since 09/16/20

Most Recent Stories

More News
RegeneRx Issues Letter To Stockholders

/PRNewswire/ --(OTCQB: RGRX) a clinical-stage drug development company focused on tissue protection, repair and regeneration, has issued a Letter to Stockholders updating its recent financing, the FDA...

RGRX : 0.1876 (-6.20%)
OTC Markets Group Announces Quarterly Index Performance and Rebalancing

/PRNewswire/ --  (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced the second quarter 2021 performance and quarterly rebalancing of the OTCQX and OTCQB...

VNNHF : 0.6769 (+1.76%)
LGORF : 15.4400 (+2.18%)
NUXFF : 1.1260 (+2.18%)
TUES : 0.2818 (+17.91%)
ABSSF : 30.0900 (-1.02%)
BKRRF : 0.6227 (-3.61%)
BSXGF : 0.4000 (-1.62%)
GPHOF : 0.7800 (+2.63%)
OBTC : 14.2500 (-1.32%)
AKCCF : 3.1000 (+4.73%)
DECPF : 1.5800 (-2.47%)
HRVSF : 3.0040 (+6.15%)
ADDYY : 168.4200 (-0.20%)
CWLPF : 1.5600 (-0.76%)
HCHDF : 1.9910 (-5.64%)
TKGBY : 1.1100 (-0.45%)
WMMVY : 35.7300 (-0.64%)
ZURVY : 42.8100 (-0.56%)
ARBV : 19.5000 (unch)
BSFO : 26.4050 (-0.36%)
CNBB : 43.0000 (-0.12%)
CWBK : 32.0000 (+1.59%)
ESBS : 5.0600 (+0.20%)
GBFH : 10.5000 (unch)
IFHI : 28.4900 (unch)
LUMB : 13.5000 (+5.88%)
LYBC : 43.9900 (unch)
OSBK : 41.1600 (+0.02%)
PBNC : 35.5500 (unch)
TYCB : 35.7000 (-0.14%)
TYFG : 47.3000 (+0.08%)
ABXXF : 2.7100 (-1.09%)
BRCHF : 0.3525 (-0.70%)
CHXMF : 0.6170 (-3.59%)
DMEHF : 2.3896 (-1.66%)
FUNFF : 0.7500 (-3.60%)
ORXOY : 4.1300 (+7.55%)
EMHTF : 0.1102 (-7.32%)
GDNSF : 1.5148 (+3.05%)
TCNNF : 27.0300 (+6.92%)
TNYBF : 0.1674 (-3.90%)
TOBAF : 3.1806 (-2.73%)
VLNCF : 1.9600 (-1.26%)
AURQF : 0.2582 (-1.75%)
BMIX : 0.0096 (-1.03%)
CMPX : 3.5000 (unch)
DGWR : 0.0140 (-6.67%)
HEWA : 0.1410 (-21.67%)
RGRX : 0.1876 (-6.20%)
STVGF : 0.0470 (+18.99%)
OTCM : 46.4000 (+0.11%)
RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome

/PRNewswire/ --a clinical-stage drug development company focused on tissue protection, repair and regeneration has released an update from its U.S. joint venture, ReGenTree LLC, regarding its progress...

RGRX : 0.1876 (-6.20%)
RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement

/PRNewswire/ -- (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that it closed its previously announced private placement...

RGRX : 0.1876 (-6.20%)
RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement

/PRNewswire/ -- (OTCQB: RGRX)a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that it has entered into a definitive agreement with certain...

RGRX : 0.1876 (-6.20%)
RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome

, /PRNewswire/ -- a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted a press release from its U.S. joint venture, ReGenTree LLC, on its website...

RGRX : 0.1876 (-6.20%)
RegeneRx Issues Update on ARISE-3 Trial

, /PRNewswire/ --(OTCQB: RGRX)a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the estimated timing of the...

RGRX : 0.1876 (-6.20%)
RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial

, /PRNewswire/ -- (OTCQB: RGRX)a clinical-stage biopharmaceutical company focused on tissue protection, repair and regeneration, announced that the ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops...

RGRX : 0.1876 (-6.20%)
RegeneRx JV Locks Clinical Trial Database for Phase 3 Dry Eye Trial

, /PRNewswire/ -- a clinical-stage biopharmaceutical company focused on tissue protection, repair and regeneration, announced that the ARISE-3 Phase 3 clinical trial database evaluating RGN-259 eyedrops...

RGRX : 0.1876 (-6.20%)
RegeneRx Comments on ARISE-3 Clinical Trial

, /PRNewswire/ --a clinical-stage drug development company focused on tissue protection, repair and regeneration, is addressing rumors in the market regarding its ARISE-3 phase 3 dry eye trial. 

RGRX : 0.1876 (-6.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 0.2169
2nd Resistance Point 0.2085
1st Resistance Point 0.1980
Last Price 0.1876
1st Support Level 0.1791
2nd Support Level 0.1707
3rd Support Level 0.1602

See More

52-Week High 0.8200
Fibonacci 61.8% 0.5736
Fibonacci 50% 0.4975
Fibonacci 38.2% 0.4214
Last Price 0.1876
52-Week Low 0.1750

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar